EDGEWELL PERSONAL CARE Co
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO FINANCIAL STATEMENTS
| Consolidated Financial Statements | |
|---|---|
| Responsibility for Financial Statements | 41 |
| Report of Independent Registered Public Accounting Firm | 42 |
| Consolidated Statements of Earnings and Comprehensive Income for the fiscal years ended September 30, 2024, 2023 and 2022. | 44 |
| Consolidated Balance Sheets as of September 30, 2024 and 2023. | 45 |
| Consolidated Statements of Cash Flows for the fiscal years ended September 30, 2024, 2023 and 2022. | 46 |
| Consolidated Statements of Changes in Shareholders’ Equity for the period from October 1, 2021 to September 30, 2024. | 48 |
| Notes to Consolidated Financial Statements. | 49 |
Responsibility for Financial Statements
The preparation and integrity of the financial statements of Edgewell Personal Care Company (the “Company”) are the responsibility of its management. These statements have been prepared in conformance with generally accepted accounting principles (“GAAP”) in the United States of America, and in the opinion of management, fairly present the Company’s financial position, results of operations and cash flows.
The Company maintains accounting and internal control systems, which it believes are adequate to provide reasonable assurance that assets are safeguarded against loss from unauthorized use or disposition and that financial records are reliable for preparing financial statements. The selection and training of qualified personnel, the establishment and communication of accounting and administrative policies and procedures, and a program of internal audits are important elements of these control systems.
The Board of Directors, through its Audit Committee consisting solely of non-management directors, meets periodically with management, internal audit and the independent auditors to discuss audit and financial reporting matters. To ensure independence, our auditor, PricewaterhouseCoopers LLP, has direct access to the Audit Committee.
To the Board of Directors and Shareholders of Edgewell Personal Care Company
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Edgewell Personal Care Company and its subsidiaries (the "Company") as of September 30, 2024 and 2023, and the related consolidated statements of earnings and comprehensive income, of changes in shareholders' equity and of cash flows for each of the three years in the period ended September 30, 2024, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended September 30, 2024 appearing under Item 15(2) (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of September 30, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of September 30, 2024, and 2023, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2024, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Goodwill Impairment Assessments – Skin Care and Feminine Care Reporting Units
As described in Notes 2 and 9 to the consolidated financial statements, the Company’s consolidated goodwill balance as of September 30, 2024 was $1,338.6 million, and the goodwill associated with the Sun and Skin Care and Feminine Care segments was $355.4 million and $206.2 million, respectively. Goodwill from the Skin Care reporting unit makes up a significant portion of the goodwill related to the Sun and Skin Care segment. Management performs their annual impairment assessment for goodwill as of July 1, or more frequently if indicators of impairment exist. The goodwill impairment test compares a reporting unit’s fair value to its carrying amount. When a quantitative test is performed, management estimates each reporting unit’s fair value using a weighted income approach and market approach. As disclosed by management, determining the fair value of a reporting unit requires the use of significant judgment, estimates and assumptions. The income approach uses the discounted cash flow method, and the key assumptions include discount rates, terminal growth rates, and future levels of revenue growth and EBITDA margins. The market approach uses the guideline public company method to calculate the fair value of each reporting unit by applying earnings multiples to the operating performance of each reporting unit, and the key assumptions include market multiples and determination of comparable publicly traded companies.
The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of the Skin Care and Feminine Care reporting units is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the Skin Care and Feminine Care reporting units; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management’s significant assumptions related to revenue growth rates and discount rate used in the discounted cash flow method for the Skin Care reporting unit, and revenue growth rates, terminal growth rate, EBITDA margins, and discount rate used in the discounted cash flow method for the Feminine Care reporting unit; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s goodwill impairment assessments, including controls over the valuation of the Company’s reporting units. These procedures also included, among others (i) testing management’s process for developing the fair value estimate of the Skin Care and Feminine Care reporting units; (ii) evaluating the appropriateness of the discounted cash flow method used by management; (iii) testing the completeness and accuracy of underlying data used in the discounted cash flow method; and (iv) evaluating the reasonableness of the significant assumptions used by management related to revenue growth rates and discount rate for the Skin Care reporting unit, and revenue growth rates, terminal growth rate, EBITDA margins, and discount rate for the Feminine Care reporting unit. Evaluating management’s assumptions related to revenue growth rates for the Skin Care reporting unit and revenue growth rates and EBITDA margins for the Feminine Care reporting unit involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the Skin Care and Feminine Care reporting units; (ii) the consistency with external relevant industry forecasts and macroeconomic conditions; (iii) management’s historical forecasting accuracy; (iv) management’s objectives and strategies; and (v) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the Company’s discounted cash flow method and (ii) the reasonableness of the discount rate assumptions for the Skin Care and Feminine Care reporting units.
/s/PricewaterhouseCoopers LLP
Stamford, Connecticut
November 14, 2024
We have served as the Company’s auditor since 1999.
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net sales | $2,253.7 | $2,251.6 | $2,171.7 |
| Cost of products sold | 1,298.0 | 1,310.8 | 1,291.2 |
| Gross profit | 955.7 | 940.8 | 880.5 |
| Selling, general and administrative expense | 430.1 | 409.6 | 389.1 |
| Advertising and sales promotion expense | 232.0 | 229.1 | 238.3 |
| Research and development expense | 58.4 | 58.5 | 55.5 |
| Restructuring charges | 35.9 | 16.6 | 15.3 |
| Operating income | 199.3 | 227.0 | 182.3 |
| Interest expense associated with debt | 76.5 | 78.5 | 71.4 |
| Other expense (income), net | 1.9 | 0.8 | (13.2) |
| Earnings before income taxes | 120.9 | 147.7 | 124.1 |
| Income tax provision | 22.3 | 33.0 | 24.6 |
| Net earnings | $98.6 | $114.7 | $99.5 |
| Earnings per share (Note 6): | |||
| Basic net earnings per share | $1.98 | $2.24 | $1.87 |
| Dilutive net earnings per share | $1.97 | $2.21 | $1.85 |
| Weighted-average shares outstanding: | |||
| Basic | 49.7 | 51.2 | 53.1 |
| Diluted | 50.1 | 51.8 | 53.6 |
| Statements of Comprehensive Income: | |||
| Net earnings | $98.6 | $114.7 | $99.5 |
| Other comprehensive income (loss), net of tax: | |||
| Foreign currency translation adjustments | 18.6 | 44.3 | (89.4) |
| Pension and postretirement activity, net of tax (benefit) provision of $(0.6) in 2024, $2.7 in 2023, and $5.2 in 2022 | 1.2 | 6.6 | 4.7 |
| Deferred (loss) gain on hedging activity, net of tax (benefit) provision of $(2.2) in 2024, $(2.2) in 2023, and $2.5 in 2022 | (4.6) | (4.8) | 5.5 |
| Total other comprehensive income (loss), net of tax | 15.2 | 46.1 | (79.2) |
| Total comprehensive income | $113.8 | $160.8 | $20.3 |
(in millions, except share data)
| September 30,2024 | September 30,2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $209.1 | $216.4 |
| Trade receivables, less allowance for doubtful accounts of $4.6 and $5.6 | 109.4 | 106.2 |
| Inventories | 477.3 | 492.4 |
| Other current assets | 140.2 | 147.4 |
| Total current assets | 936.0 | 962.4 |
| Property, plant and equipment, net | 349.1 | 337.9 |
| Goodwill | 1,338.6 | 1,331.4 |
| Other intangible assets, net | 948.5 | 973.8 |
| Other assets | 158.7 | 135.2 |
| Total assets | $3,730.9 | $3,740.7 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities | ||
| Notes payable | $24.5 | $19.5 |
| Accounts payable | 219.3 | 194.4 |
| Other current liabilities | 319.8 | 309.5 |
| Total current liabilities | 563.6 | 523.4 |
| Long-term debt | 1,275.0 | 1,360.7 |
| Deferred income tax liabilities | 133.2 | 136.4 |
| Other liabilities | 175.0 | 179.7 |
| Total liabilities | 2,146.8 | 2,200.2 |
| Commitments and contingencies (Note 19) | ||
| Shareholders’ equity | ||
| Preferred shares, $0.01 par value, 10,000,000 authorized; none issued or outstanding | — | — |
| Common shares, $0.01 par value, 300,000,000 authorized; 65,251,989 issued; 48,920,813 and 50,118,789 outstanding | 0.7 | 0.7 |
| Additional paid-in capital | 1,586.0 | 1,593.8 |
| Retained earnings | 1,090.1 | 1,022.1 |
| Common shares in treasury at cost, 16,331,176 and 15,133,200 | (937.9) | (906.1) |
| Accumulated other comprehensive loss | (154.8) | (170.0) |
| Total shareholders’ equity | 1,584.1 | 1,540.5 |
| Total liabilities and shareholders’ equity | $3,730.9 | $3,740.7 |
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash Flow from Operating Activities | |||
| Net earnings | $98.6 | $114.7 | $99.5 |
| Adjustments to reconcile net earnings to net cash flow from operations: | |||
| Depreciation and amortization | 88.0 | 91.4 | 89.9 |
| Share-based compensation expense | 26.5 | 27.5 | 23.8 |
| Deferred income taxes | (9.6) | (4.5) | (13.7) |
| Deferred compensation payments | (2.1) | (4.9) | (7.3) |
| Loss on sale of assets | 0.7 | 2.5 | 1.5 |
| Defined benefit settlement loss | — | 7.9 | — |
| Other, net | (18.7) | (23.5) | (9.6) |
| Changes in current assets and liabilities from operations, net of effects of acquisitions: | |||
| Accounts receivable, net | (7.3) | 31.0 | (6.6) |
| Inventories | 19.7 | (32.4) | (111.3) |
| Other current assets | 4.7 | 20.8 | (11.5) |
| Accounts payable | 17.0 | (30.2) | 29.3 |
| Other current liabilities | 13.5 | 15.8 | 18.0 |
| Net cash provided by operating activities | 231.0 | 216.1 | 102.0 |
| Cash Flow from Investing Activities | |||
| Capital expenditures | (56.5) | (49.5) | (56.4) |
| Acquisitions, net of cash acquired | — | — | (309.4) |
| Proceeds from sale of Infant Care business | — | — | 5.0 |
| Collection of deferred purchase price from accounts receivable sold | 0.7 | 2.7 | 6.9 |
| Other, net | (6.6) | (3.7) | (1.5) |
| Net cash used by investing activities | (62.4) | (50.5) | (355.4) |
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash Flow from Financing Activities | |||
| Cash proceeds from debt with original maturities greater than 90 days | 813.0 | 841.0 | 707.0 |
| Cash payments for debt with original maturities greater than 90 days | (901.0) | (874.0) | (552.0) |
| Net proceeds from (payments for) debt with original maturities of 90 days or less | 4.2 | — | (3.9) |
| Repurchase of shares | (58.5) | (75.2) | (125.3) |
| Dividends paid to common shareholders | (30.7) | (31.5) | (32.6) |
| Employee shares withheld for taxes | (7.3) | (9.0) | (10.7) |
| Net financing inflow (outflow) from the Accounts Receivable Facility | 5.2 | 2.3 | (0.8) |
| Other, net | (4.3) | (0.1) | 0.7 |
| Net cash used by financing activities | (179.4) | (146.5) | (17.6) |
| Effect of exchange rate changes on cash | 3.5 | 8.6 | (19.5) |
| Net (decrease) increase in cash and cash equivalents | (7.3) | 27.7 | (290.5) |
| Cash and cash equivalents, beginning of period | 216.4 | 188.7 | 479.2 |
| Cash and cash equivalents, end of period | $209.1 | $216.4 | $188.7 |
| Supplemental Disclosures of Cash Flow Information: | |||
| Cash paid for interest, net | $62.8 | $74.3 | $68.4 |
| Cash paid for income taxes, net | 33.5 | 45.8 | 23.8 |
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Common Shares · Treasury Shares | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number | Par Value | Number | Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | |
| Balance at October 1, 2021 | 65.2 | $0.7 | (10.9) | $(776.3) | $1,631.1 | $872.2 | $(136.9) | $1,590.8 |
| Net earnings | — | — | — | — | — | 99.5 | — | 99.5 |
| Dividends declared to common shareholders | — | — | — | — | — | (32.6) | — | (32.6) |
| Foreign currency translation adjustments | — | — | — | — | — | — | (89.4) | (89.4) |
| Pension and postretirement activity | — | — | — | — | — | — | 4.7 | 4.7 |
| Deferred gain on hedging activity | — | — | — | — | — | — | 5.5 | 5.5 |
| Repurchase of shares | — | — | (3.3) | (125.3) | — | — | — | (125.3) |
| Activity under share plans | — | — | 0.5 | 40.7 | (26.8) | — | — | 13.9 |
| Balance at September 30, 2022 | 65.2 | $0.7 | (13.7) | $(860.9) | $1,604.3 | $939.1 | $(216.1) | $1,467.1 |
| Net earnings | — | — | — | — | — | 114.7 | — | 114.7 |
| Dividends declared to common shareholders | — | — | — | — | — | (31.7) | — | (31.7) |
| Foreign currency translation adjustments | — | — | — | — | — | — | 44.3 | 44.3 |
| Pension and postretirement activity | — | — | — | — | — | — | 6.6 | 6.6 |
| Deferred loss on hedging activity | — | — | — | — | — | — | (4.8) | (4.8) |
| Repurchase of shares | — | — | (1.9) | (75.2) | — | — | — | (75.2) |
| Activity under share plans | — | — | 0.6 | 30.0 | (10.5) | — | — | 19.5 |
| Balance at September 30, 2023 | 65.2 | $0.7 | (15.0) | $(906.1) | $1,593.8 | $1,022.1 | $(170.0) | $1,540.5 |
| Net earnings | — | — | — | — | — | 98.6 | — | 98.6 |
| Dividends declared to common shareholders | — | — | — | — | — | (30.6) | — | (30.6) |
| Foreign currency translation adjustments | — | — | — | — | — | — | 18.6 | 18.6 |
| Pension and postretirement activity | — | — | — | — | — | — | 1.2 | 1.2 |
| Deferred loss on hedging activity | — | — | — | — | — | — | (4.6) | (4.6) |
| Repurchase of shares including excise tax | — | — | (1.6) | (59.3) | — | — | — | (59.3) |
| Activity under share plans | — | — | 0.3 | 27.5 | (7.8) | — | — | 19.7 |
| Balance at September 30, 2024 | 65.2 | $0.7 | (16.3) | $(937.9) | $1,586.0 | $1,090.1 | $(154.8) | $1,584.1 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1 -Background and Basis of Presentation
Background
Edgewell Personal Care Company and its subsidiaries (collectively, “Edgewell” or the “Company”) is one of the world’s largest manufacturers and marketers of personal care products in the wet shave, sun and skin care and feminine care categories. With operations in over 20 countries, the Company’s products are widely available in more than 50 countries.
The Company conducts its business in the following three segments:
Wet Shave consists of products sold under the Schick®, Wilkinson Sword®, Edge, Skintimate®, Billie®, Shave Guard and our custom brands group (formerly sold under our Shave Guard and Personna® brands), as well as non-branded products. The Company’s wet shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams.
Sun and Skin Care consists of Banana Boat® and Hawaiian Tropic® sun care products, Jack Black®, Bulldog® and Cremo® men’s and women’s grooming products, Billie women’s grooming products and Wet Ones® products.
Feminine Care includes tampons, pads and liners sold under the Playtex Gentle Glide® and Sport®, Stayfree®, Carefree®, and o.b.® brands.
Basis of Presentation
The accompanying Consolidated Financial Statements include the accounts of the Company and its controlled subsidiaries and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) under the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ materially from those estimates. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included.
Certain immaterial prior year amounts have been reclassified to conform with the current year’s presentation.
Acquisition of Billie, Inc. On November 29, 2021 (“the Acquisition Date”), the Company completed the acquisition of Billie, Inc. (“Billie”) (the “Acquisition”), a leading U.S. based consumer brand company that offers a broad portfolio of personal care products for women. The results of Billie for the post-acquisition period are included within the Company’s results since the Acquisition Date. For more information on the Acquisition, see Note 3 of Notes to the Consolidated Financial Statements.
Note 2 -Summary of Significant Accounting Policies
Cash Equivalents
Cash equivalents are considered to be highly liquid investments with a maturity of three months or less when purchased. At September 30, 2024, the Company had $209.1 in available cash and cash equivalents, a significant portion of which was outside of the U.S. The Company has extensive operations outside of the U.S., including a significant manufacturing footprint. The Company manages its worldwide cash requirements by reviewing available funds among the many subsidiaries through which it conducts its business and the cost effectiveness with which those funds can be accessed. The repatriation of cash balances from certain of the Company’s subsidiaries could have adverse tax consequences or be subject to regulatory capital requirements; however, those balances are generally available without legal restrictions to fund ordinary business operations.
Cash Flow Presentation
The Consolidated Statements of Cash Flows are prepared using the indirect method, which reconciles Net earnings to Net cash from operating activities. The reconciliation adjustments include the removal of timing differences between the occurrence of operating receipts and payments and their recognition in Net earnings. The adjustments also remove cash flows arising from investing and financing activities, which are presented separately from operating activities. Cash flows from foreign currency transactions and operations are translated at an average exchange rate for the period. Cash flows from hedging activities are included in the same category as the items being hedged, which are primarily operating activities. Cash payments related to income taxes are classified as operating activities.
Trade Receivables
Trade receivables are stated at their net realizable value. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the trade receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Bad debt expense is included in Selling, general and administrative expense (“SG&A”) in the Consolidated Statements of Earnings and Comprehensive Income. The Company has two accounts receivable factoring programs. For further discussion, see Note 11 of Notes to Consolidated Financial Statements.
Inventories
Inventories are valued at the lower of cost or market value, with cost generally determined using average cost or the first-in, first-out (“FIFO”) method.
Capitalized Software Costs
Capitalized software costs are included in Property, plant and equipment, net. These costs are amortized using the straight-line method over periods of related benefit ranging from three toseven years. Expenditures related to capitalized software are included within Capital expenditures in the Consolidated Statements of Cash Flows.
Property, Plant and Equipment, net
Property, plant and equipment, net (“PP&E”) is stated at historical cost. PP&E acquired as part of a business combination is recorded at estimated fair value. Expenditures for new facilities and expenditures that substantially increase the useful life of property, including interest during construction, are capitalized and reported as Capital expenditures in the accompanying Consolidated Statements of Cash Flows. Maintenance, repairs and minor renewals are expensed as incurred. When property is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts and gains or losses on the disposition are reflected in Net earnings. Depreciation is generally provided on the straight-line basis by charges to earnings at rates based on estimated useful lives. Estimated useful lives range fromtwo to 10 years for machinery and equipment andthree to 30 years for buildings and building improvements.
Estimated useful lives are periodically reviewed and, when appropriate, changes are made and accounted for prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts.
Leases
The Company leases certain offices and manufacturing facilities, warehouses, employee vehicles and certain manufacturing related equipment. A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified PP&E over a contracted period in exchange for payment. The Company evaluates if an arrangement is a lease as of the effective date of the agreement. Certain leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included within the lease term when it has become reasonably certain that the Company will exercise such options. Operating lease ROU assets and operating lease liabilities are recorded based on the present value of minimum payments over the lease term at the effective date of the lease. Any costs in excess of the minimum payments are expensed as incurred as variable lease cost.
Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheet. All recorded leases are classified as operating leases and lease expense is recognized on a straight-line basis over the lease term. The Company has elected as an accounting policy not to separate non-lease components from lease components and, instead, account for these components as a single lease component. For leases that do not provide an implicit rate, the Company uses its secured incremental borrowing rate, based on the information available for leases, including the lease term and interest rate environment in the country in which the lease exists, to calculate the present value of the future lease payments.
Business Combinations
The Company allocates the cost of an acquired business to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess value of the cost of an acquired business over the estimated fair value of the assets acquired and liabilities assumed is recognized as goodwill. The valuation of the acquired assets and liabilities will impact the determination of future operating results.
The Company uses a variety of information sources to determine the value of acquired assets and liabilities, including: third-party appraisers for the values and lives of property, identifiable intangibles and inventories; actuaries for defined benefit retirement plans; and legal counsel or other experts to assess the obligations associated with legal, environmental or other claims.
Goodwill and Other Intangible Assets
We perform our annual impairment assessment for goodwill and indefinite-lived intangible assets as of July 1st and more frequently if indicators of impairment exist. We consider qualitative factors to assess if it is more likely than not that the fair value for goodwill or indefinite-lived intangible assets is below the carrying amount. We may also elect to bypass the qualitative assessment and perform a quantitative assessment.
In conducting a qualitative assessment, the Company analyzes a variety of events and factors that may influence the fair value of the reporting unit or indefinite-lived intangible asset, including, but not limited to: macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, share price and other relevant factors
Goodwill
We have four reporting units for which we assess for impairment defined as Wet Shave, Sun Care, Skin Care and Feminine Care. We evaluate goodwill for impairment using either a qualitative or quantitative assessment.
When the qualitative assessment is not utilized and a quantitative test is performed, we estimate each reporting unit’s fair value using a weighted income approach and market approach. The income approach uses the reporting unit's projections of estimated operating results and cash flows that are discounted using a market participant discount rate based on a weighted-average cost of capital. The market approach uses market multiples of comparable companies.
The goodwill impairment test compares a reporting unit’s fair value to its carrying amount. If the fair value of the reporting unit exceeds its carrying amount, no impairment loss is measured. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, then a goodwill impairment loss is measured at the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill.
For further discussion, see Note 9 of Notes to Consolidated Financial Statements.
Other Intangible Assets
Our indefinite-lived intangible assets primarily consist of trade names. We evaluate these intangible assets for impairment using either a qualitative or quantitative assessment.
When a quantitative test is performed, we determine the fair value using one of two income approaches: (i) the multi-period excess earnings method or (ii) the relief-from-royalty method. These methods require assumptions regarding future revenue and operating margin growth, estimated returns on assets used in the operations (including net working capital, fixed assets and intangible assets), market participant discount rates based on a weighted-average cost of capital and assumed royalty rates if we did not own the trade name.
Other definite-life intangible assets, have a remaining weighted-average life of approximately eight years, are amortized on a straight-line basis over expected lives of three to 25 years. These intangible assets are assessed for impairment when impairment indicators are present.
For further discussion, see Note 9 of Notes to Consolidated Financial Statements.
Impairment of Long-Lived Assets
The Company reviews long-lived assets, other than goodwill and other intangible assets, for impairment when events or changes in business circumstances indicate that the remaining useful life may warrant revision or that the carrying amount of the long-lived asset may not be fully recoverable. The Company performs an undiscounted cash flow analysis to determine if impairment exists for an asset or asset group. If impairment is determined to exist, any related impairment loss is calculated based on estimated fair value. Impairment losses on assets to be disposed of, if any, are based on the estimated proceeds to be received, less cost of disposal.
Revenue Recognition
Principal Revenue Streams and Significant Judgments
Our principal revenue streams can be divided into: (i) sale of personal care products primarily through retailers in North America; (ii) sale of personal care products through a combination of retailers and distributors internationally; and (iii) production and sale of private brands products in North America and internationally that are made to customer specifications.
Performance Obligations
The Company’s revenue is generated from the sale of its products. Revenue is recognized when the customer obtains control of the goods, which occurs when the ability to use and obtain benefits from the goods are passed to the customer, most commonly upon the delivery of goods to the customer. Discounts are offered to customers for early payment and an estimate of discounts is recorded as a reduction of Net sales in the same period as the sale. The Company’s standard sales terms are final and returns or exchanges are not permitted with the exception of end-of-season returns for Sun Care products. Reserves are established and recorded in cases where the right of return exists for a particular sale.
The Company assesses the goods promised in its customers’ purchase orders and identifies a performance obligation to transfer goods (or a bundle of goods) that is distinct. To identify the performance obligations, the Company considers all the goods promised, whether explicitly stated or implied based on customary business practices. The Company’s purchase orders are short term in nature, lasting less than one year and contain a single delivery element. For a purchase order that has more than one performance obligation, the Company allocates the total consideration to each distinct performance obligation on a relative stand-alone selling price basis. The Company does not exclude variable consideration in determining the remaining value of performance obligations.
Significant Judgments
The Company records sales at the time that control of goods pass to the customer. The terms of these sales vary but the following conditions are applicable to all sales: (i) the sales arrangement is evidenced by purchase orders submitted by customers; (ii) the selling price is fixed or determinable; (iii) title to the product has transferred; (iv) there is an obligation to pay at a specified date without any additional conditions or actions required by the Company; and (v) collectability is reasonably assured. Simultaneously with the sale, the Company reduces Net sales and Cost of products sold and reserves amounts on its Consolidated Balance Sheet for anticipated returns based upon an estimated return level in accordance with GAAP. The Company also allows for returns of other products under limited circumstances. Customers are required to pay for the Sun Care product purchased during the season under the required terms. Under certain circumstances, the Company allows customers to return Sun Care products that have not been sold by the end of the Sun Care season, which is normal practice in the Sun Care industry. The timing of returns of Sun Care products can vary in different regions based on climate and other factors. However, the majority of returns occur in the U.S. from September through January following the summer Sun Care season. The Company estimates the level of Sun Care returns as the Sun Care season progresses using a variety of inputs, including historical experience, consumption trends during the Sun Care season, obsolescence factors including expiration dates and inventory positions at key retailers. The Company monitors shipment activity and inventory levels at key retailers during the Sun Care season in an effort to more accurately estimate potential returns. This allows the Company to manage shipment activity to its customers, especially in the latter stages of the Sun Care season, to reduce the potential for returned product. The Company also allows for returns of other products under limited circumstances. Non-Sun Care returns are evaluated each period based on communications with customers and other issues known as of period end. The Company had a reserve for returns of $50.3 and $53.5 at September 30, 2024 and 2023, respectively.
In addition, the Company offers a variety of programs, such as consumer coupons and rebate programs, primarily to its retail customers, designed to promote sales of its products. Such programs require periodic payments and allowances based on estimated results of specific programs and are recorded as a reduction to Net sales. The Company accrues, at the time of sale, the estimated total payments and allowances associated with each transaction. Additionally, the Company offers programs directly to consumers to promote the sale of its products. Promotions which reduce the ultimate consumer sale price are recorded as a reduction of Net sales at the time the promotional offer is made using estimated redemption and participation levels. Taxes the Company collects on behalf of governmental authorities, which are generally included in the price to the customer, are also recorded as a reduction of Net sales. The Company continually assesses the adequacy of accruals for customer and consumer promotional program costs not yet paid. To the extent total program payments differ from estimates, adjustments may be necessary. Historically, these adjustments have not been material.
Contract Balances
The timing of revenue recognition is based on completion of performance obligations through the transfer of goods. Standard payment terms with customers require payment after goods have been delivered and risk of ownership has transferred to the customer. The Company has contract liabilities as a result of advanced payments received from certain customers before goods have been delivered and all performance obligations have been completed. Contract liabilities were $1.1 and $0.6 at September 30, 2024 and 2023, respectively, and were classified within Other current liabilities on our Consolidated Balance Sheets. Substantially all of the amount deferred will be recognized within a year, with the significant majority to be captured within a quarter following deferral.
Trade receivables are stated at their net realizable value. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in its trade receivables portfolio determined by historical experience, specific allowances for known troubled accounts, and other currently available information.
Advertising and Sales Promotion Costs
The Company advertises and promotes its products through national and regional media and expenses such activities as incurred. Advertising and sales promotion expense reported on the Consolidated Statements of Earnings and Comprehensive Income includes advertising costs of $127.1, $116.0 and $125.8 for fiscal 2024, 2023 and 2022, respectively.
Share-Based Payments
The Company grants restricted share equivalents (“RSE”), which generally vest overtwo tofour years. The estimated fair value of each grant is estimated on the date of grant based on the current market price of the Company’s common shares. The original estimate of the grant date fair value is not subsequently revised unless the awards are modified. The Company has elected to recognize forfeiture of awards as they occur. A portion of the RSE awards provide for the issuance of common stock to certain managerial staff and executive management if the Company achieves specified performance targets. For Performance Restricted Share Equivalents (“PRSE”), the Company records estimated expense for performance-based grants based on target achievement of performance metrics for the three-year period for each respective program, unless evidence exists that achievement above or below target for the applicable performance metric is more likely to occur. For PRSE awards granted during fiscal 2024, 2023 and 2022, awards will vest by comparing the Company’s total shareholder return (“TSR”) during a certain three-year period to the respective TSRs of companies in a selected performance peer group. The expense recorded for these awards was recorded on a straight-line basis based on the grant date fair value using a Monte Carlo simulation.
Non-qualified stock options (“Share Options”) are granted at the market price on the grant date and generally vest ratably over three years. The Company calculates the fair value of total share-based compensation for Share Options using the Black-Scholes option pricing model, which utilizes certain assumptions and estimates that have a material impact on the total compensation cost recognized in the Consolidated Financial Statements, including the expected term, expected share price volatility, risk-free interest rate and expected dividends. The original estimate of the grant date fair value is not subsequently revised unless the awards are modified. The Company has elected to recognize forfeiture of awards as they occur.
Income Taxes
The Company’s annual effective income tax rate is determined based on its pre-tax income, statutory tax rates and the tax impacts of items treated differently for tax purposes than for financial reporting purposes. Tax law requires that certain items be included in its federal tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in the Company’s tax return, and some differences are temporary, reversing over time, such as depreciation expense. These temporary differences create deferred tax assets and liabilities.
Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which the Company has already recorded the tax benefit in the Consolidated Statement of Earnings and Comprehensive
Income. Deferred tax liabilities generally represent tax expense recognized in the Company’s financial statements for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in its tax return but has not yet been recognized in its financial statements or assets recorded at estimated fair value in business combinations for which there was no corresponding tax basis adjustment.
The Company estimates income taxes and the effective income tax rate in each jurisdiction that it operates. This involves estimating taxable earnings, specific taxable and deductible items, the likelihood of generating sufficient future taxable income to utilize deferred tax assets, the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable and possible exposures related to future tax audits. Deferred tax assets are evaluated on a subsidiary by subsidiary basis to ensure that the asset will be realized. Valuation allowances are established when the realization is not deemed to be more likely than not. Future performance is monitored, and when objectively measurable operating trends change, adjustments are made to the valuation allowances accordingly. To the extent the estimates described above change, adjustments to income taxes are made in the period in which the estimate is changed.
The Company operates in multiple jurisdictions with complex tax and regulatory environments, which are subject to differing interpretations by the taxpayer and the taxing authorities. At times, the Company may take positions that management believes are supportable but are potentially subject to successful challenges by the appropriate taxing authority. The Company evaluates its tax positions and establishes liabilities in accordance with guidance governing accounting for uncertainty in income taxes. The Company reviews these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjusts them accordingly.
Estimated Fair Values of Financial Instruments
Certain financial instruments are required to be recorded at estimated fair value. Changes in assumptions or estimation methods could affect the fair value estimates; however, the Company does not believe any such changes would have a material impact on its financial condition, results of operations or cash flows. Other financial instruments including cash and cash equivalents and short-term borrowings, including notes payable, are recorded at cost, which approximates estimated fair value. The estimated fair values of long-term debt and financial instruments are disclosed in Note 18 of Notes to Consolidated Financial Statements.
Foreign Currency Translation
Financial statements of foreign operations where the local currency is the functional currency are translated using end-of-period exchange rates for assets and liabilities, and average exchange rates during the period for results of operations. Related translation adjustments are reported as a component within accumulated other comprehensive loss in the shareholders’ equity section of the Consolidated Balance Sheets, except as noted below.
Gains and losses resulting from foreign currency transactions are included in Net earnings. Foreign currency gains (losses) of $1.9, $1.7 and $(7.7) during fiscal 2024, 2023 and 2022, respectively, were included within Other expense (income), net in the Consolidated Statements of Earnings and Comprehensive Income. The Company uses foreign exchange (“FX”) instruments to reduce the risk of FX transactions as described below and in Note 18 of Notes to Consolidated Financial Statements.
Financial Instruments and Derivative Securities
The Company uses financial instruments, from time to time, in the management of foreign currency, interest rate, and other risks that are inherent to its business operations. Such instruments are not held or issued for trading purposes.
FX instruments, including forward currency contracts, are used primarily to reduce cash transaction exposures and, to a lesser extent, to manage other translation exposures. FX instruments are selected based on their risk reduction attributes, costs, and related market conditions. The Company has designated certain foreign currency contracts as cash flow hedges for accounting purposes as of September 30, 2024.
At September 30, 2024, the Company had $34.0 of variable rate debt outstanding. In the past the Company has used interest rate swaps to hedge the risk of variable rate debt. As of September 30, 2024, the Company did not have any outstanding interest rate swap agreements.
For further discussion, see Note 13 and Note 18 of Notes to Consolidated Financial Statements.
Recently Issued Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures to update income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively and early adoption is permitted. We are currently assessing the impact of the requirements on our consolidated financial statements and disclosures.
In November 2023, the FASB issued ASUNo. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to expand reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in the ASU require that a public entity disclose, on an annual and interim basis, significant segment expenses that are regularly provided to an entity's chief operating decision maker (“CODM”), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. Annual disclosures are required for fiscal years beginning after December 15, 2023. Interim disclosures are required for periods within fiscal years beginning after December 15, 2024. Retrospective application is required for all prior periods presented and early adoption is permitted. We are currently assessing the impact of the requirements on our consolidated financial statements and disclosures.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial Statements.
Recently Adopted Accounting Pronouncements
In September 2022, the FASB issued Accounting Standards Update 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations" which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users including a rollforward of those obligations. The Company adopted the standard as of October 1, 2023, except for amendments relating to the rollforward requirement, which is effective for fiscal years beginning after December 15, 2023.
The Company has agreements with its suppliers in the ordinary course of business for such supplier finance programs which facilitate participating suppliers’ ability to finance payment obligations of the Company with designated third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers’ decisions to finance amounts under these arrangements. The payment terms under the programs range from 60 to 120 days. As of September 30, 2024 and September 30, 2023, $16.9 and $21.8, respectively, were valid obligations under the various programs. The obligations are presented as Accounts payable on the Condensed Consolidated Balance Sheets.
Note 3 -Business Combinations
Billie Inc.
On November 29, 2021, the Company completed the Billie Acquisition for cash consideration of $309.4, net of cash acquired. As a result of the Acquisition, Billie became a wholly owned subsidiary of the Company. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including goodwill, other intangible assets and deferred taxes, requires significant judgement. The Company has calculated fair values of the assets and liabilities acquired from Billie, including goodwill, intangible assets and working capital. The Company completed the final fair value determination of the Acquisition in the fourth quarter of fiscal year 2022.
The Company used variations of the income approach in determining the fair value of intangible assets acquired in the Billie Acquisition. Specifically, we utilized the multi-period excess earnings method to determine the fair value of the definite lived customer relationships acquired and the relief from royalty method to determine the fair value of the definite lived trade name acquired. Our determination of the fair value of the intangible assets acquired involved the use of significant estimates and assumptions related to revenue growth rates, discount rates, customer attrition rates, and royalty rates. Edgewell believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use.
The following table provides the allocation of the purchase price related to the Billie Acquisition based upon the fair value of assets and liabilities assumed:
| Current assets | $17.0 |
|---|---|
| Goodwill | 181.2 |
| Intangible assets | 136.0 |
| Other assets, including property, plant and equipment, net | 3.2 |
| Current liabilities | (6.9) |
| Deferred tax liabilities | (21.1) |
| $309.4 |
The acquired goodwill represented the value of expansion into new markets and channels of trade and is not deductible for tax purposes. The intangible assets acquired consisted primarily of the Billie trade name and customer relationships with a weighted average useful life of 19 years. All assets are included in the Company’s Wet Shave segment.
Billie contributed net sales and a loss before income taxes totaling $93.7 and $1.1, respectively, for the post-acquisition period ending September 30, 2022 in the Consolidated Statements of Earnings and Comprehensive Income. The loss before income taxes was driven primarily by amortization expense of acquired intangible assets.
The following acquisition and integration costs related to Billie were included in SG&A and Cost of products sold in the Consolidated Statements of Earnings and Comprehensive Income:
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| SG&A | $2.8 | $7.5 | $9.1 |
| Cost of products sold | 3.3 | — | 0.8 |
| Total acquisition and integration costs | $6.1 | $7.5 | $9.9 |
The following summarizes the Company's unaudited pro forma consolidated results of operations for the twelve months ended September 30, 2022, as though the Billie Acquisition occurred on October 1, 2021. The twelve months ended September 30, 2022 include results of Billie over the full period presented.
| Twelve Months Ended September 30, | |
|---|---|
| Pro forma net sales | $2,181.7 |
| Pro forma net earnings | 104.9 |
The unaudited pro forma consolidated results of operations were adjusted by pre-tax amortization expense of $1.3 for the year ended September 30, 2022. Additionally, pro forma earnings for the twelve months ended September 30, 2022 exclude $9.9 of pre-tax acquisition costs, which were included in the pro forma earnings for the twelve months ended September 30, 2021. The pro forma earnings were also adjusted to reflect the capital structure as of the Acquisition Date, and all pro forma adjustments have been included with related tax effects. The unaudited pro forma consolidated results of operations are not necessarily indicative of the results obtained had the Billie Acquisition occurred on October 1, 2020, or of those results that may be obtained in the future. Amounts do not reflect any anticipated cost savings or cross-selling opportunities expected to result from the Billie Acquisition.
Note 4 -Restructuring Charges
Operating Model Redesign
In fiscal 2024, the Company continued to take actions to strengthen its operating model, simplify the organization and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, the Company expects to incur restructuring and re-positioning charges of approximately $11 in fiscal 2025. To date the Company has incurred restructuring and related charges as follows:
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Severance and related benefit costs | $10.2 | $6.2 | $5.6 |
| Asset write-off and accelerated depreciation | 0.6 | 0.8 | 0.8 |
| Consulting, project implementation and management, and other exit costs | 9.6 | 10.1 | 9.8 |
| Total restructuring and repositioning charges (1) (2) | $20.4 | $17.1 | $16.2 |
(1) Restructuring and repositioning charges ofnil, $0.2 andnil are included within Cost of products sold for fiscal 2024, 2023 and 2022, respectively.
(2) Restructuring and repositioning charges of $0.1, $0.3 and $0.9 are included within SG&A for fiscal 2024, 2023 and 2022, respectively.
Consolidation of Mexico Facilities
In fiscal 2024, the Company announced certain operational and organizational steps designed to streamline the Company’s operations and supply chain by consolidating its current Mexico operations in Obregon and Mexico City into a single facility in Aguascalientes, Mexico. As a result of these actions, the Company is anticipating to incur restructuring and re-positioning charges of $18 in fiscal 2025 and is expected to be completed by the second quarter of fiscal 2026.
| Fiscal Year | |
|---|---|
| 2024 | |
| Severance and related benefit costs | $15.6 |
| Total restructuring and repositioning charges (1) | $15.6 |
(1) The Company does not include restructuring costs in the results of its reportable segments, however, these are related to the Wet Shave segment.
Restructuring Reserves
| Operating Model Redesign | Consolidation of Mexico Facilities | Total | |
|---|---|---|---|
| Severance and related benefit costs | |||
| Balance at October 1, 2022 | $1.7 | $— | $1.7 |
| Charge to income | 6.2 | — | 6.2 |
| Cash payments | (4.0) | — | (4.0) |
| Balance at September 30, 2023 | 3.9 | — | 3.9 |
| Charge to income | 10.8 | 15.6 | 26.4 |
| Cash payments | (9.6) | — | (9.6) |
| Balance at September 30, 2024 | 5.1 | 15.6 | 20.7 |
| Asset write-off and accelerated depreciation | |||
| Balance at October 1, 2022 | — | — | — |
| Charge to income | 0.8 | — | 0.8 |
| Non-cash utilization | (0.8) | — | (0.8) |
| Balance at September 30, 2023 | — | — | — |
| Consulting, project implementation and management, and other exit costs | |||
| Balance at October 1, 2022 | 0.8 | — | 0.8 |
| Charge to income | 10.1 | — | 10.1 |
| Cash payments | (10.2) | — | (10.2) |
| Balance at September 30, 2023 | 0.7 | — | 0.7 |
| Charge to income | 9.6 | — | 9.6 |
| Cash payments | (9.6) | — | (9.6) |
| Balance at September 30, 2024 | 0.7 | — | 0.7 |
| Total restructuring activities and related accrual | $5.8 | $15.6 | $21.4 |
Note 5 -Income Taxes
The provisions for income taxes from continuing operations consisted of the following:
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Currently payable: | |||
| United States - Federal | $6.3 | $12.5 | $12.4 |
| State | 0.2 | 3.5 | 6.6 |
| Foreign | 25.4 | 21.5 | 19.4 |
| Total current | 31.9 | 37.5 | 38.4 |
| Deferred: | |||
| United States - Federal | (4.8) | (4.5) | (7.6) |
| State | 1.5 | (0.6) | (0.6) |
| Foreign | (6.3) | 0.6 | (5.6) |
| Total deferred | (9.6) | (4.5) | (13.8) |
| Income tax provision | $22.3 | $33.0 | $24.6 |
The source of pre-tax earnings was:
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| United States | $(13.3) | $37.6 | $2.6 |
| Foreign | 134.2 | 110.1 | 121.5 |
| Pre-tax earnings | $120.9 | $147.7 | $124.1 |
A reconciliation of income taxes with the amounts computed at the statutory federal income tax rate follows:
| Fiscal Year | ||||||
|---|---|---|---|---|---|---|
| 2024 · 2023 · 2022 | ||||||
| Computed tax at federal statutory rate | $25.4 | 21.0% | $31.0 | 21.0% | $25.8 | 21.0% |
| State income taxes, net of federal tax benefit | 0.9 | 0.7 | 2.7 | 1.8 | 2.7 | 2.2 |
| Foreign tax less than the federal rate (1) | (9.1) | (7.6) | (1.0) | (0.7) | (11.7) | (9.5) |
| Adjustments to prior years’ tax accruals | (4.3) | (3.5) | (6.1) | (4.2) | 1.6 | 1.3 |
| Other taxes including repatriation of foreign earnings | 7.1 | 5.9 | 4.4 | 3.1 | 4.6 | 3.7 |
| Compensation adjustments | 4.0 | 3.4 | 1.9 | 1.2 | 3.4 | 2.7 |
| Other, net | 1.7 | 1.4 | (0.5) | (0.3) | 0.5 | 0.5 |
| Uncertain tax positions | (3.4) | (2.8) | 0.6 | 0.4 | (2.3) | (2.0) |
| Total | $22.3 | 18.5% | $33.0 | 22.3% | $24.6 | 19.9% |
(1) Includes the impact of foreign valuation allowances.
The deferred tax assets and deferred tax liabilities recorded on the Consolidated Balance Sheet include current and noncurrent amounts and were as follows:
| September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Deferred tax liabilities: | ||
| Depreciation and property differences | $(18.3) | $(20.8) |
| Amortizable assets | (229.3) | (230.2) |
| Lease liabilities | (23.1) | (15.2) |
| Other tax liabilities | (7.3) | (4.3) |
| Gross deferred tax liabilities | (278.0) | (270.5) |
| Deferred tax assets: | ||
| Accrued liabilities | 54.2 | 56.6 |
| Deferred and share-based compensation | 14.4 | 14.9 |
| Tax carryforwards and tax credits | 51.1 | 37.3 |
| Postretirement benefits other than pensions | 1.3 | 1.0 |
| Pension plans | 28.0 | 25.0 |
| Inventory differences | 5.9 | 5.0 |
| Lease right of use assets | 23.3 | 15.3 |
| Deferred revenue | 4.2 | 7.0 |
| Other tax assets | 9.4 | 8.0 |
| Gross deferred tax assets | 191.8 | 170.1 |
| Valuation allowance | (21.5) | (18.3) |
| Net deferred tax liabilities | $(107.7) | $(118.7) |
There were no material tax loss carryforwards that expired in fiscal 2024. Future expirations of tax loss carryforwards and tax credits, if not utilized, are not expected to be material from 2025 through 2041. The remaining tax loss carryforwards and credits have no expiration. The valuation allowance is primarily attributable to tax loss carryforwards, other carryforwards, and certain deferred tax assets impacted by the deconsolidation of the Company’s Venezuelan subsidiaries.
The Company generally repatriates a portion of current year earnings from select non-US subsidiaries only if the economic cost of the repatriation is not considered material. No provision is made for additional taxes on undistributed earnings of foreign affiliates that are intended and planned to be indefinitely invested in the affiliate. The Company intends to, and has plans to, reinvest these earnings indefinitely in its foreign subsidiaries to, amongst other things, fund local operations, fund pension and other post-retirement obligations, fund capital projects and to support foreign growth initiatives including potential acquisitions. As of September 30, 2024, $885.8 of foreign subsidiary earnings were considered indefinitely invested in those businesses. If the Company repatriated any of the earnings it could be subject to withholding tax and the impact of foreign currency movements. Accordingly, it is not practical to calculate a specific potential tax exposure. Applicable income and withholding taxes will be provided on these earnings in the periods in which they are no longer considered reinvested.
Unrecognized tax benefits activity is summarized below:
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Unrecognized tax benefits, beginning of year | $19.7 | $19.4 | $21.9 |
| Additions based on current year tax positions and acquisitions | 2.1 | 1.9 | 2.1 |
| Settlements with taxing authorities and statute expirations | (5.2) | (1.6) | (4.6) |
| Unrecognized tax benefits, end of year | $16.6 | $19.7 | $19.4 |
Included in the unrecognized tax benefits noted above was $15.7 of uncertain tax positions that would affect the Company’s effective tax rate, if recognized. The Company does not expect any material increases or decreases to its unrecognized tax benefits within 12 months of this reporting date. In the Consolidated Balance Sheets, unrecognized tax benefits are classified as Other liabilities (non-current) to the extent that payments are not anticipated within one year.
The Company classifies accrued interest and penalties related to unrecognized tax benefits in the income tax provision. The accrued interest and penalties are not included in the table above. The Company accrued $3.9 of interest, (net of the deferred tax asset of $0.7) at September 30, 2024, and $4.4 of interest, (net of the deferred tax asset of $0.8) at September 30, 2023. Interest was computed on the difference between the tax position recognized in accordance with GAAP and the amount previously taken or expected to be taken in the Company’s tax returns.
The Company files income tax returns in the U.S. federal jurisdiction, various cities and states, and more than 30 foreign jurisdictions where the Company has operations. In general, U.S. federal income tax returns for tax years ended September 30, 2021 and after remain subject to examination by the Internal Revenue Service (the “IRS”). With few exceptions, the Company is no longer subject to state and local income tax examinations for years before September 30, 2014. The status of international income tax examinations varies by jurisdiction. At this time, the Company does not anticipate any material adjustments to its financial statements resulting from tax examinations currently in progress.
Note 6 -Earnings per Share
Basic earnings per share is based on the average number of common shares outstanding during the period. Diluted earnings per share is based on the average number of shares used for the basic earnings per share calculation, adjusted for the dilutive effect of share options, RSE, and PRSE awards.
The following is the reconciliation between the number of weighted-average shares used in the basic and diluted earnings per share calculation:
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Basic weighted-average shares outstanding | 49.7 | 51.2 | 53.1 |
| Effect of dilutive securities: | |||
| Options, RSE and PRSE awards | 0.4 | 0.6 | 0.5 |
| Total dilutive securities | 0.4 | 0.6 | 0.5 |
| Diluted weighted-average shares outstanding | 50.1 | 51.8 | 53.6 |
The following weighted-average common shares were excluded from the calculation of diluted net earnings per share because the effect of including these awards was antidilutive.
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Options, RSE and PRSE awards | 1.3 | 1.2 | 1.0 |
Note 7 -Inventories
The following table summarizes our inventories at September 30, 2024 and 2023:
| September 30,2024 | September 30,2023 | |
|---|---|---|
| Inventories | ||
| Raw materials and supplies | $82.6 | $86.3 |
| Work in process | 91.8 | 91.1 |
| Finished products | 302.9 | 315.0 |
| Total inventories | $477.3 | $492.4 |
Note 8 -Property, Plant and Equipment
The following table summarizes our PP&E, net at September 30, 2024 and 2023:
| Estimated Useful Life | September 30,2024 | September 30,2023 | |
|---|---|---|---|
| PP&E | |||
| Land | n/a | $18.9 | $18.5 |
| Buildings | 3 - 30 years | 147.9 | 142.6 |
| Machinery and equipment | 2 - 10 years | 1,132.7 | 1,105.3 |
| Capitalized software costs | 3 - 7 years | 62.5 | 60.2 |
| Construction in progress | n/a | 62.0 | 38.5 |
| Total gross property, plant and equipment | 1,424.0 | 1,365.1 | |
| Accumulated depreciation | (1,074.9) | (1,027.2) | |
| Total PP&E | $349.1 | $337.9 | |
The components of depreciation expense for PP&E, net and amortization expense for capitalized software costs were as follows:
| Fiscal Year | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Depreciation expense | $52.7 | $55.6 | $55.7 |
| Amortization expense associated with capitalized software | 4.3 | 5.0 | 4.7 |
As of September 30, 2024, the Company had $5.8, included in accounts payable for the acquisition of PP&E, which is considered a non-cash investing activity in the Consolidated Statements of Cash Flows.
Note 9 -Goodwill and Intangible Assets
The following table sets forth goodwill by segment:
| WetShave | Sun and Skin Care | FeminineCare | Total | |
|---|---|---|---|---|
| Gross balance at October 1, 2022 | $1,133.5 | $354.5 | $205.2 | $1,693.2 |
| Accumulated goodwill impairment | (369.0) | (2.0) | — | (371.0) |
| Net balance at October 1, 2022 | $764.5 | $352.5 | $205.2 | $1,322.2 |
| Cumulative translation adjustment | 7.0 | 1.4 | 0.8 | $9.2 |
| Gross balance at October 1, 2023 | $1,140.5 | $355.9 | $206.0 | $1,702.4 |
| Accumulated goodwill impairment | (369.0) | (2.0) | — | (371.0) |
| Net balance at October 1, 2023 | $771.5 | $353.9 | $206.0 | $1,331.4 |
| Cumulative translation adjustment | 5.5 | 1.5 | 0.2 | 7.2 |
| Gross balance at September 30, 2024 | $1,146.0 | $357.4 | $206.2 | $1,709.6 |
| Accumulated goodwill impairment | (369.0) | (2.0) | — | (371.0) |
| Net balance at September 30, 2024 | $777.0 | $355.4 | $206.2 | $1,338.6 |
The Company performed its annual goodwill impairment analysis as of July 1, 2024. The Company elected to perform a qualitative assessment of goodwill impairment for the Sun Care reporting unit and a quantitative assessment for the Wet Shave, Skin Care and Fem Care reporting units. Based on the results of the qualitative and quantitative assessments, we determined there were no impairments of our reporting units.
The Company also performed an impairment assessment in the fourth quarter of fiscal 2024 to determine if any significant events or changes in circumstances had occurred in our reporting units since the annual impairment testing date that would be considered a potential triggering event. The Company did not identify any triggering events that would indicate the existence of an impairment of the reporting units.
Total intangible assets were as follows:
| September 30, 2024 | September 30, 2023 | |||||
|---|---|---|---|---|---|---|
| GrossCarryingAmount | AccumulatedAmortization | Net | GrossCarryingAmount | AccumulatedAmortization | Net | |
| Indefinite lived | ||||||
| Trade names and brands | $597.7 | $— | $597.7 | $592.9 | $— | $592.9 |
| Definite lived | ||||||
| Trade names and brands | $339.8 | $(104.0) | $235.8 | $339.6 | $(88.1) | $251.5 |
| Technology and patents | 79.7 | (77.3) | 2.4 | 79.4 | (76.2) | 3.2 |
| Customer related and other | 272.5 | (159.9) | 112.6 | 269.8 | (143.6) | 126.2 |
| Amortizable intangible assets | $692.0 | $(341.2) | $350.8 | $688.8 | $(307.9) | $380.9 |
| Total intangible assets | $1,289.7 | $(341.2) | $948.5 | $1,281.7 | $(307.9) | $973.8 |
The Company’s annual indefinite-lived intangible assets impairment analysis was conducted on July 1, 2024. The Company elected to bypass the qualitative assessment and perform a quantitative assessment of the Schick and Bulldog trade names. We performed a qualitative test of impairment for all other indefinite-lived intangible assets. Based on the results of the quantitative and qualitative assessments, we determined there were no impairments of the carrying values of the indefinite-lived intangible assets.
The Company also performed an impairment assessment in the fourth quarter of fiscal 2024 to determine if any significant events or changes in circumstances had occurred in our indefinite-lived intangible assets since the annual impairment testing date that would be considered a potential triggering event. The Company did not identify any triggering events that would indicate the existence of an impairment of the indefinite-lived intangible assets.
Amortization expense for definite lived intangible assets was $31.1, $30.8 and $29.4 for fiscal 2024, 2023 and 2022, respectively.
Estimated amortization expense for amortizable intangible assets is as follows:
| Estimated amortization expense | |
|---|---|
| Fiscal 2025 | $31.1 |
| Fiscal 2026 | $30.8 |
| Fiscal 2027 | $30.5 |
| Fiscal 2028 | $30.5 |
| Fiscal 2029 | $30.4 |
| Thereafter | $197.5 |
Note 10 -Leases
A summary of the Company's lease information is as follows:
| September 30,2024 · September 30,2023 | |||
|---|---|---|---|
| Assets · Classification | |||
| Right of use assets | Other assets | $85.4 | $68.5 |
| Liabilities | |||
| Current lease liabilities | Other current liabilities | $16.7 | $14.0 |
| Long-term lease liabilities | Other liabilities | 69.8 | 53.9 |
| Total lease liabilities | $86.5 | $67.9 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.